FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078362485> ?p ?o ?g. }

• W2078362485 endingPage "282" @default.
• W2078362485 startingPage "277" @default.
• W2078362485 abstract "The aim of this study was to determine the toxicity, response rate, failure-free survival, and overall survival in a treatment program comprising continuous infusion carboplatin, short in-fusion 5-fluorouracil (5-FU) and radiotherapy for localized carcinoma of the thoracic esophagus. To be eligible, patients were required to have Karnofsky performance status greater than or equal to 60, adequate organ function, and have received no prior therapy. Planned radiation dose was 50 Gy in 25 fractions over 5 weeks. 5-FU was to be administered commencing days 1 and 29 of radiotherapy, and given at a dose of 1 g/m2/d for 4 days as a continuous infusion. Carboplatin was to commence on day 1 of radiotherapy and be given throughout the period of radiation as a continuous infusion. The starting dose of carboplatin was 28 mg/m2/d. The protocol specified a 25% dose reduction of carboplatin if more than two of the first six patients experienced dose-limiting toxicity (DLT). DLT was defined as grade IV neutropenia lasting more than 7 days, grade IV thrombocytopenia, or any grade IV nonhematologic toxicity. All 23 patients in the study received protocol radio-therapy, except one who was given an extra 10 Gy. Seven patients received carboplatin at 28 mg/m2/d and 16 received 21 mg/m2/d. Hematologic DLTs were experienced by all of the seven patients receiving the higher dose. No patients in the low-dose group experienced hematologic DLTs, and only 2 of 16 ceased chemotherapy early because of myelosuppression. Three patients in the low-dose group experienced grade IV esophagitis but were able to complete protocol radiotherapy. Apart from esophagitis, nonhematologic toxicity was generally moderate or mild. Six patients had thrombosis complicating the central venous catheters. Endoscopy was performed in 21 patients (91%), with an overall complete response rate of 65% (CI: 43–84%) for the whole group or 71% (CI: 48–89%) for the endoscopically evaluated group. Estimated median failure-free survival time was 8.9 months (CI: 7.1–12.9), and estimated median overall survival time was 21.4 months (CI: 9.6 –35.4). Carboplatin at 21 mg/m2/d as a continuous infusion may be given safely in combination with short infusional 5-FU and radiotherapy for localized carcinoma of the esophagus. This combination has resulted in response data comparable to that of larger studies of cisplatin-containing regimens and warrants further study, ideally in a phase III randomized controlled trial." @default.
• W2078362485 created "2016-06-24" @default.
• W2078362485 creator A5001910534 @default.
• W2078362485 creator A5023248242 @default.
• W2078362485 creator A5057450798 @default.
• W2078362485 creator A5060114622 @default.
• W2078362485 creator A5060469120 @default.
• W2078362485 creator A5085480227 @default.
• W2078362485 date "2002-06-01" @default.
• W2078362485 modified "2023-09-26" @default.
• W2078362485 title "Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus" @default.
• W2078362485 cites W1896070059 @default.
• W2078362485 cites W1908474666 @default.
• W2078362485 cites W1965583792 @default.
• W2078362485 cites W1978564090 @default.
• W2078362485 cites W1979350836 @default.
• W2078362485 cites W1994865959 @default.
• W2078362485 cites W1995482480 @default.
• W2078362485 cites W1996156310 @default.
• W2078362485 cites W2011207121 @default.
• W2078362485 cites W2014564927 @default.
• W2078362485 cites W2031772203 @default.
• W2078362485 cites W2038180810 @default.
• W2078362485 cites W2039612753 @default.
• W2078362485 cites W2044889252 @default.
• W2078362485 cites W2045657776 @default.
• W2078362485 cites W2051784631 @default.
• W2078362485 cites W2059272559 @default.
• W2078362485 cites W2061106638 @default.
• W2078362485 cites W2094699565 @default.
• W2078362485 cites W2100801123 @default.
• W2078362485 cites W2117092135 @default.
• W2078362485 cites W2119696360 @default.
• W2078362485 cites W2134042196 @default.
• W2078362485 cites W2144263975 @default.
• W2078362485 cites W2167805334 @default.
• W2078362485 cites W2212101069 @default.
• W2078362485 cites W2333908381 @default.
• W2078362485 doi "https://doi.org/10.1097/00000421-200206000-00015" @default.
• W2078362485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12040288" @default.
• W2078362485 hasPublicationYear "2002" @default.
• W2078362485 type Work @default.
• W2078362485 sameAs 2078362485 @default.
• W2078362485 citedByCount "9" @default.
• W2078362485 countsByYear W20783624852013 @default.
• W2078362485 countsByYear W20783624852016 @default.
• W2078362485 countsByYear W20783624852017 @default.
• W2078362485 crossrefType "journal-article" @default.
• W2078362485 hasAuthorship W2078362485A5001910534 @default.
• W2078362485 hasAuthorship W2078362485A5023248242 @default.
• W2078362485 hasAuthorship W2078362485A5057450798 @default.
• W2078362485 hasAuthorship W2078362485A5060114622 @default.
• W2078362485 hasAuthorship W2078362485A5060469120 @default.
• W2078362485 hasAuthorship W2078362485A5085480227 @default.
• W2078362485 hasConcept C126322002 @default.
• W2078362485 hasConcept C126894567 @default.
• W2078362485 hasConcept C141071460 @default.
• W2078362485 hasConcept C2776694085 @default.
• W2078362485 hasConcept C2777063308 @default.
• W2078362485 hasConcept C2777819096 @default.
• W2078362485 hasConcept C2778239845 @default.
• W2078362485 hasConcept C2780456651 @default.
• W2078362485 hasConcept C2781451048 @default.
• W2078362485 hasConcept C29730261 @default.
• W2078362485 hasConcept C509974204 @default.
• W2078362485 hasConcept C71924100 @default.
• W2078362485 hasConcept C90924648 @default.
• W2078362485 hasConceptScore W2078362485C126322002 @default.
• W2078362485 hasConceptScore W2078362485C126894567 @default.
• W2078362485 hasConceptScore W2078362485C141071460 @default.
• W2078362485 hasConceptScore W2078362485C2776694085 @default.
• W2078362485 hasConceptScore W2078362485C2777063308 @default.
• W2078362485 hasConceptScore W2078362485C2777819096 @default.
• W2078362485 hasConceptScore W2078362485C2778239845 @default.
• W2078362485 hasConceptScore W2078362485C2780456651 @default.
• W2078362485 hasConceptScore W2078362485C2781451048 @default.
• W2078362485 hasConceptScore W2078362485C29730261 @default.
• W2078362485 hasConceptScore W2078362485C509974204 @default.
• W2078362485 hasConceptScore W2078362485C71924100 @default.
• W2078362485 hasConceptScore W2078362485C90924648 @default.
• W2078362485 hasIssue "3" @default.
• W2078362485 hasLocation W20783624851 @default.
• W2078362485 hasLocation W20783624852 @default.
• W2078362485 hasOpenAccess W2078362485 @default.
• W2078362485 hasPrimaryLocation W20783624851 @default.
• W2078362485 hasRelatedWork W1991613108 @default.
• W2078362485 hasRelatedWork W2094700497 @default.
• W2078362485 hasRelatedWork W2147181545 @default.
• W2078362485 hasRelatedWork W2170402962 @default.
• W2078362485 hasRelatedWork W2291289025 @default.
• W2078362485 hasRelatedWork W2348495938 @default.
• W2078362485 hasRelatedWork W2350597429 @default.
• W2078362485 hasRelatedWork W2418474598 @default.
• W2078362485 hasRelatedWork W2460868461 @default.
• W2078362485 hasRelatedWork W2461744023 @default.
• W2078362485 hasVolume "25" @default.
• W2078362485 isParatext "false" @default.
• W2078362485 isRetracted "false" @default.

• next